Catalog No.
Product Name
Application
Product Information
Citations
-
HSD17B13 Inhibitor
HSD17B13-IN-6 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. This compound is valuable for investigating the role of HSD17B13 in liver diseases, providing insights that may contribute to the understanding of metabolic disorders and potential therapeutic targets. Researchers can utilize HSD17B13-IN-6 to explore biochemical pathways associated with liver function and disease processes. -
HSD17B13 Inhibitor
HSD17B13-IN-80-d2 is a deuterium-labeled inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is essential for investigating the role of HSD17B13 in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its unique labeling enhances tracking and analysis in metabolic research applications. -
17β-HSD10 Inhibitor
17β-HSD10-IN-3 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) with an IC50 value of 5.59 μM. This compound demonstrates a lack of cytotoxicity in the HEK-293 cell line at concentrations up to 20 μM. It is suited for research applications investigating the role of 17β-HSD10 in steroid metabolism and neurodegenerative diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-76 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for research into liver diseases and metabolic disorders, facilitating studies on the biochemical pathways regulated by HSD17B13 and its role in steroid metabolism. -
17β-HSD3 Inhibitor
BMS-856 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3). It demonstrates potent inhibitory activity with IC50 values of 60 nM in enzyme assays and 300 nM in whole cell assays, effectively disrupting the enzyme's activity. BMS-856 is valuable for research focused on steroidogenesis and potential therapeutic applications in hormonal disorders, particularly those related to testosterone metabolism. -
HSD17B13 Inhibitor
HSD17B13-IN-74 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound serves as a valuable tool in the study of liver diseases and metabolic disorders, enabling the exploration of HSD17B13's role in steroid metabolism. Its potent inhibition can facilitate research into therapeutic strategies targeting related pathologies. -
HSD17B13 Inhibitor
HSD17B13-IN-86 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its ability to modulate HSD17B13 activity makes it a useful tool in the exploration of therapeutic strategies for these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-52 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver conditions, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies related to drug-induced liver injury (DILI). -
HSD17B13 Inhibitor
HSD17B13-IN-103 is a selective inhibitor of the enzyme HSD17B13. This compound demonstrates potential in research focused on non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Its inhibition of HSD17B13 may provide insights into therapeutic strategies for metabolic liver diseases. -
17β-HSD3 Inhibitor
SCH-451659 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) with an IC50 of 2.4 nM. By blocking the conversion of androstenedione to testosterone, SCH-451659 effectively lowers testosterone levels in vivo. This compound exhibits potential anticancer activity, particularly against prostate tumors that depend on androstenedione. Its specific targeting mechanism makes SCH-451659 a valuable reagent for research in hormone-related cancer therapies. -
HSD17B13 Inhbitor
HSD17B13-IN-62 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver diseases (NAFLD), providing valuable insights into the mechanisms of lipid metabolism and hormone regulation. Its application may aid in the development of therapeutic strategies targeting liver dysfunction and associated metabolic disorders. -
17β-HSD Inhibitor
HSD17B13-IN-17 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values of less than 0.1 μM for estradiol and under 1 μM for Leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-17 is essential for research focused on the modulation of lipid metabolism and the therapeutic potential of HSD17B13 inhibitors in liver-related disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-66 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for researching liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specificity and efficacy make it a promising tool for elucidating the role of HSD17B13 in various pathophysiological processes. -
HSD17B13 Inhibitor
HSD17B13-IN-65 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is instrumental in research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its targeted action on HSD17B13 allows for the exploration of therapeutic strategies in these areas. -
17β-HSD Inhibitor
HSD17B13-IN-27 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is instrumental in research involving nonalcoholic fatty liver diseases (NAFLD), including nonalcoholic steatohepatitis (NASH). Its ability to modulate steroid hormone metabolism positions it as a valuable tool for studying metabolic disorders and developing therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-13 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver pathologies, including non-alcoholic fatty liver disease (NAFLD). Its potent inhibitory activity makes it a useful tool for elucidating the biochemical mechanisms underlying liver disorders and developing therapeutic strategies. -
17β-HSD Inhibitor
HSD17B13-IN-19 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol and below 1 μM for leukotriene B3. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its inhibition of HSD17B13 may provide insights into therapeutic strategies for managing liver-related metabolic disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-80-d3 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD) and may serve as a valuable tool for studying metabolic regulation and liver-related pathologies. -
HSD17B13 Inhibitor
HSD17B13-IN-75 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. Additionally, HSD17B13-IN-75 can be utilized in studies focused on drug-induced liver injury (DILI). -
HSD17B13 Inhibitor
HSD17B13-IN-46 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is utilized in research focused on liver diseases and metabolic disorders, providing valuable insights into the modulation of steroid hormone regulation and related pathophysiologies. Its high specificity and efficacy make it a significant tool for further investigations in these areas. -
HSD17B13 Inhibitor
HSD17B13-IN-32 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound demonstrates significant potential for research applications in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition may facilitate the investigation of HSD17B13's role in these pathologies. -
17β-HSD5 Inhibitor
EM 1404 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) with an IC50 of 3.2 nM. This compound plays a crucial role in modulating androgen metabolism and has significant implications in the study of hormone-related disorders. EM 1404 is valuable for research focused on exploring therapeutic strategies for conditions associated with altered steroid hormone levels. -
HSD17B13 Inhibitor
HSD17B13-IN-39 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), a key enzyme implicated in lipid metabolism and liver function. This compound is particularly relevant for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. HSD17B13-IN-39 provides essential insights into the role of HSD17B13 in disease mechanisms and potential therapeutic interventions. -
17β-HSD Inhibitor
HSD17B13-IN-1 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM with estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-1 provides valuable insights into the biochemical pathways involved in fatty liver disease and serves as a potential therapeutic target for related conditions. -
17β-HSD Inhibitor
HSD17B13-IN-31 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is crucial in researching nonalcoholic fatty liver diseases (NAFLDs), particularly nonalcoholic steatohepatitis (NASH), by modulating lipid metabolism and inflammation. HSD17B13-IN-31 serves as a valuable tool for studying the role of HSD17B13 in liver-related disorders and therapeutic interventions. -
AKR1C3 Inhibitor
CRT0083914 is a selective non-carboxylate inhibitor of the enzyme AKR1C3. This compound exhibits significant biological activity against AKR1C3, making it a valuable tool for studying its role in colon cancer. Researchers can utilize CRT0083914 to explore its potential therapeutic effects and mechanistic insights in the context of cancer research. -
17β-HSD Inhibitor
HSD17B13-IN-42 targets hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) as a potent inhibitor, exhibiting an IC50 of less than 0.1 μM with estradiol substrates. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it a valuable tool for researchers investigating metabolic disorders and liver pathologies. -
HSD17B13 Inhbitor
HSD17B13-IN-37 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is utilized in research focused on nonalcoholic fatty liver disease (NAFLD), where it aids in elucidating the role of HSD17B13 in lipid metabolism and liver pathophysiology. Its potent inhibitory activity makes it a valuable tool for investigating therapeutic strategies targeting HSD17B13-related pathways. -
HSD17B13 Inhibitor
HSD17B13-IN-102 is a potent inhibitor of the enzyme hydroxysteroid dehydrogenase 17 beta 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM with estradiol. This compound is instrumental in research focused on steroid metabolism and associated diseases, particularly in the context of liver function and metabolic disorders. Its selective inhibition provides a valuable tool for investigating the biological roles of HSD17B13 in various physiological and pathological conditions. -
17β-HSD Inhibitor
HSD17B13-IN-16 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound has significant relevance in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-16 serves as a valuable tool for researchers investigating metabolic disorders and potential therapeutic interventions in liver diseases. -
17β-HSD Inhibitor
HSD17B13-IN-35 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM when estradiol is used as a substrate. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), by targeting metabolic pathways involved in lipid metabolism. Its effective inhibition of HSD17B13 makes it a valuable reagent for research into therapeutic strategies for liver-related disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-63 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research applications related to liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its efficacy in modulating HSD17B13 activity provides insights into the underlying mechanisms of these diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-57 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is relevant for investigations into liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-57 serves as a valuable tool for studying the biochemical pathways involved in these diseases. -
17β-HSD Inhibitor
HSD17B13-IN-28 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its ability to modulate HSD17B13 activity makes it a valuable tool for exploring the metabolic mechanisms underpinning liver disorders and evaluating potential therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-100 is a potent inhibitor of HSD17B13, exhibiting an IC50 value of less than 0.1 μM in the presence of estradiol. This compound is essential for researchers investigating the role of HSD17B13 in steroid metabolism and related pathways. Its selective inhibition can facilitate studies on various conditions associated with altered steroidogenesis, including liver diseases and metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-80 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound plays a crucial role in research focusing on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibitory activity makes it a valuable tool for investigating the pathophysiological mechanisms underlying these diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-44 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating its role in liver diseases and metabolic disorders, providing insights into the biochemical pathways associated with these conditions. Researchers can utilize HSD17B13-IN-44 to explore therapeutic targets and validate the significance of HSD17B13 in various biological processes. -
HSD17B13 Inhibitor
HSD17B13-IN-45 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is instrumental in exploring pathways associated with liver diseases and metabolic disorders. Researchers can utilize HSD17B13-IN-45 to investigate the role of HSD17B13 in various biological contexts and its potential as a therapeutic target. -
HSD17B13 Inhibitor
HSD17B13-IN-81 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is utilized in research focused on liver diseases, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a valuable tool in studies related to drug-induced liver injury (DILI). -
17β-HSD Inhibitor
HSD17B13-IN-40 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 of less than 0.1 μM against estradiol substrates. This compound is significant for research related to nonalcoholic fatty liver diseases (NAFLD), particularly nonalcoholic steatohepatitis (NASH), as it may provide insights into the modulation of lipid metabolism and inflammatory pathways. The compound's inhibitory action on HSD17B13 highlights its potential utility in exploring therapeutic strategies for metabolic disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-58 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in the research of nonalcoholic fatty liver diseases (NAFLD), contributing to the understanding of lipid metabolism and hormonal regulation in hepatic disorders. Its selective inhibition offers valuable insights into therapeutic strategies targeting HSD17B13 in liver-related diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-33 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound plays a crucial role in research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective activity makes it a valuable tool for investigating the therapeutic potential in these diseases. -
17β-HSD Inhibitor
HSD17B13-IN-30 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol substrates. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), due to its role in modulating steroid metabolism and fatty liver progression. HSD17B13-IN-30 facilitates research into therapeutic approaches for liver-related metabolic disorders. -
17β-HSD1 Inhibitor
17β-HSD1-IN-2 is a non-estrogenic, steroidal covalent irreversible inhibitor of 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting a Ki of 368 nM. This compound demonstrates potential for studying estrogen-dependent disorders, facilitating research into therapeutic strategies for conditions influenced by estrogen metabolism. Its selective inhibition of 17β-HSD1 offers valuable insights into the enzyme's role in various biological processes and disease states. -
HSD17B13 Inhibitor
HSD17B13-IN-14 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is valuable for research into hepatic conditions, metabolic diseases, and cardiovascular disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition of HSD17B13 makes it an important tool for studying the underlying mechanisms of these diseases. -
HSD17B13 synthesis reducer
Gatuzosiran is a small interfering RNA (siRNA) that targets and reduces the synthesis of 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13). This compound plays a crucial role in research focused on fatty liver disease, providing insights into the molecular mechanisms underlying lipid metabolism and liver function. Its ability to modulate HSD17B13 expression makes it a valuable tool for studying the pathophysiology of liver diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-53 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver-related pathologies, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies on drug-induced liver injury (DILI). -
HSD17B13 Inhibitor
HSD17B13-IN-47 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for studying the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into therapeutic interventions targeting these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-83 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is relevant for investigations into liver and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specificity and efficacy make it a valuable tool for advancing research in the fields of hepatology and cardiovascular health. -
HSD17B13 Inhbitor
HSD17B13-IN-62-d3 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition provides valuable insights into the therapeutic potential for addressing metabolic liver disorders.
